| ²é¿´: 484 | »Ø¸´: 2 | |||
| µ±Ç°Ö÷ÌâÒѾ´æµµ¡£ | |||
hansom999Òø³æ (СÓÐÃûÆø)
|
[½»Á÷]
Ö¬·¾×éÖ¯Ô´»ùÖÊϸ°û£¨ADSCs):ϸ°ûѧ¹¤³ÌµÄÐÂÑ¡Ôñ
|
||
|
Ŀǰ£¬³ÉÌå¸Éϸ°ûÔÚ×éÖ¯ÔÙÉúºÍÐÞ¸´µÄÑо¿Öеõ½¹ã·ºÓ¦Ó㬸Éϸ°ûÒÆÖ²ÖÎÁƼ±ÐÔ Ð£ËÀÒ²³ÉΪ½üÄêÀ´Ñо¿µÄÈȵ㡣ÓÃÓÚ»ù´¡ºÍÁÙ´²Ñо¿µÄ¸Éϸ°ûÖ÷ÒªÓÐÅßÌ¥¸Éϸ °û¡¢¹Ç÷À¼¡ÎÀÐÇϸ°û¡¢¹ÇËè¼ä³äÖʸÉϸ°ûµÈ[1¡«3]£¬Ñо¿Ö¤Ã÷ͨ¹ýÒÆÖ²ÕâЩ¸Éϸ°û ¿ÉÒÔ¼õÉÙ¹£ËÀÃæ»ý£¬¸ÄÉÆÐļ¡ÖØËÜ£¬´Ó¶ø¸ÄÉÆÐÄÔ๦ÄÜ[4]¡£ÅßÌ¥¸Éϸ°ûÖ»ÄܽøÐÐÒì ÌåÒÆÖ²£¬À´Ô´À§ÄÑ£¬²»½ö´æÔÚÃâÒßÅųâµÄÎÊÌ⣬»¹Éæ¼°µ½Â×ÀíѧµÄÎÊÌâ¡£¹Ç÷À¼¡ÎÀ ÐÇϸ°ûºÍ¹ÇËè¸Éϸ°ûÊôÓÚ³ÉÌå¶àÄܸÉϸ°û£¬¿ÉÒÔ½øÐÐ×ÔÌåÒÆÖ²£¬±ÜÃâÁËÉÏÊöÎÊÌ⣬ µ«×ÔÌå¹Ç÷À¼¡ÎÀÐÇϸ°ûÈ¡²ÄÀ§ÄÑ£¬Ä¿Ç°Ñо¿¼°Ó¦Óý϶àµÄÊǹÇËèÀ´Ô´¸Éϸ°û¡£µ«¹Ç ËèÀ´Ô´¸Éϸ°ûÒ²´æÔÚÀ´Ô´²»×㣬ȡ²ÄÀ§ÄÑ,¸ø»¼Õß´øÀ´½Ï¶àÍ´¿àËùÒÔ½ÏÄÑΪÈËÃÇËù½Ó ÊܵÈȱµã£¬Òò´ËÐèҪѰÕÒÒ»ÖÖеĸüÒ×±»»¼Õß½ÓÊܵĸÉϸ°ûÀ´Ô´¡£Ö¬·¾×é֯ͬ¹ÇËè Ò»Ñù£¬Ò²´ÓÖÐÅß²ã·Ö»¯·¢Óý¶øÀ´£¬²¢º¬ÓдóÁ¿µÄÒ×·ÖÀëµÄÖ§³Öϸ°û¡£2001Ä꣬ZUK[ 5]µÈ´ÓÈ˵ÄÖ¬·¾×éÖ¯Öгɹ¦·ÖÀë³ö¾ßÓжàÏò·Ö»¯Ç±ÄܵĻùÖÊϸ°û£¨Adipose tissue -derived stromal cells, ADSCs£©£¬ÓëÆäËü³ÉÌå¸Éϸ°ûÏà±È£¬Ö¬·¾À´Ô´µÄ»ùÖÊϸ°û È¡²Ä¸ü·½±ã£¬¸üÈÝÒ×»ñÈ¡¡£ÕâÒ»·¢ÏÖΪ¸Éϸ°ûµÄÀ´Ô´ÌṩÁËеÄÑ¡Ôñ¡£ 1 ADSCµÄÃüÃû ADSCÔÚÒÔÍùÑо¿Öнз¨²»¾¡Ïàͬ£¬ÓеijÆÎªPLA(processed lipoaspirate c ells)[5,6], ÓеijÆÖ®ÎªÖ¬·¾À´Ô´¸Éϸ°û£¨adipose-derived stem cells£©[7]¡¢Ö¬ ·¾À´Ô´»ùÖÊϸ°û£¨adipose-derived stromal cells, ADSC£©[8] ¡¢Ö¬·¾À´Ô´¼ä³äÖÊ £¨¸É£©Ï¸°û£¨adipose-derived mesenchymal/stem cells£©[9,10]¡¢Ö¬·¾À´Ô´³ÉÌå ¸Éϸ°û£¨Adipose-derived adult stem cells£©[11]£¬»¹ÓеijÆÎªÇ°Ö¬·¾Ï¸°û[12] £¨preadipocyte£©, ÆäʵÖÊÉÏÒ²ÊÇÕâȺϸ°û¡£ÕâЩ²»Í¬µÄ½Ð·¨ËµÃ÷¶ÔÕâȺϸ°ûÉÐȱ ·¦×ã¹»µÄÁ˽âºÍͳһµÄÈÏʶ£¬Èç¶Ôϸ°ûµÄÆðÔ´¡¢±íÐÍ¡¢¹¦ÄÜ·Ö»¯µÈµÈ¡£¶øADSCÔ½À´ Ô½±»ÈËÃÇËù½ÓÊÜ£¬ÒòΪÕâÒ»½Ð·¨¸üÄÜ·´Ó³³ö¸Ãϸ°ûµÄÀ´Ô´ºÍÌØÐÔ[13]¡£ 2 ADSCµÄ»ñÈ¡ ADSCÓëMSC Ò»Ñù£¬ÔÚÍâÐÎÉϱíÏÖËÆ³ÉÏËάϸ°û¡£¶øÇÒ£¬ADSCÔÚÆ¤ÏÂÖ¬·¾ÖÐµÄ º¬Á¿ÊÇÊ®·Ö·á¸»µÄ¡£Óë¹ÇËèÀ´Ô´¼ä³äÖʸÉϸ°ûÏà±È£¬ADSCµÄÌáÈ¡¸ü·½±ã¡£¹ÇËè¼ä³ä ÖʸÉϸ°ûÖ»ÊǹÇËèµ¥¸öºËϸ°ûȺÖеļ«Ð¡Ò»²¿·Ö¡£Í¨³£Í¨¹ýÂé×íϳéÈ¡¹ÇË裬²ÉÓà ·Ö²ãÀëÎöµÄ·½·¨»ñÈ¡¹ÇËè±³µ¥¸öºËϸ°ûȺ£¬¶øµ¥¸öºËϸ°ûȺÖоø´ó²¿·ÖÊÇÔìѪ¸Éϸ °û£¬¶øÍ¨¹ýÅàÑøÆ¿Ìù±Úɸѡºó£¬¹ÇËè¼ä³äÖʸÉϸ°ûÖ»Õ¼Ìù±Úϸ°ûµÄ0.001%[5]¡£¶øA DSCµÄÌáÈ¡Ïà¶Ô¸üÈÝÒ×£¬Á¿¸ü¶à¡£Zuk[6]µÈÓ¦ÓÃÕæ¿Õ³éÎü¼¼Êõ´ÓÈËÆ¤Ï³éȡ֬·¾£¬Í¨ ¹ýIÐͽºÔøÏû»¯Ìù±ÚµÄ·½·¨¹²´Ó300 mlÎü³ö×éÖ¯ÖлñµÃ£¨2¡«6£©¡Á108¸ö³ÉÏËάϸ °ûÑùϸ°û£¬ÓÃÁ÷ʽϸ°û¼¼Êõ¼ì²â»ñµÃµÄϸ°û±íÃæASO2£¨¼ä³äÖÊÀ´Ô´Ï¸°ûÌØÒìÐÔ¿¹Ô £©±íÃ÷¾ø´ó¶àÊýϸ°û£¨85%¡À12.8%£©Îª¼ä³äÖÊÀ´Ô´µÄϸ°û£¬½öÓÐÉÙÁ¿µÄÍâÆ¤Ï¸°û¡¢ ÄÚÆ¤Ï¸°ûºÍƽ»¬¼¡Ï¸°û¡£Ö¬·¾Ç°Ìåϸ°û£¨¿É½øÒ»²½·ÖÁѲ¢·Ö»¯ÎªÖ¬·¾£©Ò²½öÕ¼0.02 %¡£Ò²¾ÍÊÇ˵£¬´Ó1 ml³éÎü×éÖ¯¿ÉÒÔ»ñµÃµÄϸ°ûÊýÁ¿¼¶ÔÚ105¡£ÎÒÃǵÄÑо¿£¨ÉÐδ·¢ ±í£©±È½ÏÁËÈ®µÄƤÏÂÖ¬·¾ºÍ¹ÇËèÌáÈ¡¸Éϸ°ûµÄÄÜÁ¦Ò²·¢ÏÖ£¬Ã¿¿ËÖ¬·¾¿É»ñÈ¡µÄÌù±Ú µÄÔ´ú»ùÖÊϸ°ûÊýÔÚ106¸ö×óÓÒ£»¶ø¹ÇËèͨ¹ýÌݶȷֲãÀëÐĵķ½·¨»ñµÃµÄµ¥¸öºËϸ°û ȺԼÿºÁÉý£¨0.5¡«1£©¡Á107¡£Èç¹û¿¼Âǵ½¹ÇËè¼ä³äÖʸÉϸ°ûÖ»Õ¼ÆäÖеÄ0.001%¡«0 .01%£¬ÔòÿºÁÉý¹ÇËèÖ»¿É»ñµÃ102¡«103ÊýÁ¿¼¶µÄMSC¡£¶øÇÒÔÚÌåÍâ½øÐÐÅàÑøÀ©Ôö£¬A DSC¶ÔÅàÑø»ùûÓÐÌØÊâÒªÇó£¬À©ÔöѸËÙ£¬¾¶à´ú´«ÅàÑø£¬±¶Ôöʱ¼ä±£³ÖÎȶ¨£¨Ô¼60 h£©¡£AILHAUD GERARDÉêÇëµÄÃÀ¹úרÀûUS2004229351[14]³Æ£¬´Ó³ÉÈËÖ¬·¾×éÖ¯ÖÐ·Ö ÀëµÃµ½µÄ¶àÄܸÉϸ°û£¬¾ßÓжËÁ£Ã¸»îÐÔ¡¢HLA ¢ñÒõÐÔ±íÐÍ£¨Á÷ʽϸ°ûÒǼì²â£©¡¢Õý ³£È¾É«Ìå×é¡¢¾ßÓÐÖÁÉÙ130´ú·ÖÁÑÔöÖ³µÄ×ÔÎÒ¸üÐÂÄÜÁ¦¡£¶øÇÒÖ¬·¾×éÖ¯º¬Á¿·á¸»,Ô¶ ´óÓÚ¹ÇËè×éÖ¯,Òò¶øÓпÉÄÜ´ÓÖ¬·¾×éÖ¯ÖзÖÀë³ö³ä×ãµÄ»ùÖʸÉϸ°û,²»¾¹ýÅàÑø¶øÖ± ½ÓÓÃÓÚϸ°ûÒÆÖ²ÖÎÁÆ¡£ 3 ADSCµÄ¼ø¶¨ ADSCÓë¹ÇËè¼ä³äÖʸÉϸ°ûÊ®·ÖÏàËÆ£¬¶þÕß¶¼´ú±íÁËͨ¹ýÅàÑøÆ¿ÄÚÕ³¸½·¨´ÓÖ¬·¾ ¿âÖзÖÀëµÄ»ùÖÊϸ°û²¿·Ö£¬Ö»²»¹ýǰÕßÊÇÀ´Ô´ÓÚÆ¤ÏÂÖ¬·¾£¬ºóÕßÀ´Ô´ÓÚ¹ÇËèÖ¬·¾¡£ ¶þÕßµÄϸ°û±íÃæ¿¹Ô±êÖ¾Ò²´ó²¿·ÖÏàͬ£¬½öÓкÜС²îÒì¡£Gronthos S[15]µÈÑо¿·¢ ÏÖ£¬È˵ÄADSCÓë¹ÇËè¼ä³äÖʸÉϸ°û±íÃæ±êÖ¾CD9£¬CD10£¬CD13£¬CD29,CD34£¬CD44£¬ CD49(d)£¬CD49(e)£¬CD54£¬CD55£¬CD59£¬CD105£¬CD146ºÍCD166Ïàͬ£»De Ugarte D A[16]µÈÈËÑо¿ÁË5ÀýÖ¬·¾³éÎüÊõ»¼ÕßÀ´Ô´µÄ¹ÇËè¼ä³äÖʸÉϸ°ûºÍÖ¬·¾¸Éϸ°û±íÃæÏÔ ÐÍ¡£½«PLAÖ¬·¾Ï¸°ûºÍBM-MSC·ÖÀë¡¢´«´ú£¬È»ºóͨ¹ýÁ÷ʽϸ°ûÒǼø¶¨ÁËϸ°û±íÃæ±êÖ¾ ¡£PLAºÍBM-MSCϸ°û¾ù±í´ïCD13, CD29£¬CD44£¬CD90£¬CD105£¬SH-3ºÍSTRO-1£¬¶øÏ¸ °ûÕ³¸½·Ö×ÓCD49d(Õ³ºÏËØ-¦Á4),CD54(ICAM-1),CD34ºÍCD106 (VCAM-1)µÄ±í´ï²»Í¬¡£ ÕâЩ²»Í¬µÄϸ°ûÕ³¸½·Ö×ÓÓëÔìѪ¸Éϸ°ûµÄ¹é³²¡¢¶¯Ô±ºÍÔöÖ³Óйء£NakagamiµÈ[17] Ñо¿C57B1/6СÊóÒ²·¢ÏÖADSC±í´ïSca1(ly-6A/E)£¨¸Éϸ°û¿¹Ôly-6A/E£¬Ð¡ÊóÔìѪ¸É ϸ°û±êÖ¾·Ö×Ó£©ºÍCD44¿¹Ô£¬µ«²»±í´ï c-kit(СÊó¶àÄܸÉϸ°û±íÃæÑôÐÔ·Ö×Ó±êÖ¾Ö® Ò»)£¬Lin(СÊó¶àÄܸÉϸ°û±íÃæÒõÐÔ·Ö×Ó±êÖ¾)£¬CD11 b£¬CD31£¬CD34£¬CD45¡£¶øÇÒ £¬ÕâЩϸ°û±íÃæ±êÖ¾Ëæ¶à´Î´«´úÅàÑø±í´ïÎȶ¨¡£ÎÒÃǶԴóÊóµÄADSCµÄÑо¿·¢ÏÖ£¬Ï¸ °ûÁ¬Ðø´«´ú11´ú£¬Ï¸°û±íÃæ±ê¼ÇÎ޸ı䡣 ´ÓÒÔÉÏÑо¿·¢ÏÖ£¬²»Í¬µÄÑо¿¶ÔÓÚ±íÃæ±êÖ¾CD34ÊÇ·ñÑôÐÔ½á¹û²»Í¬¡£ÓÐÑо¿ [18]·¢ÏÖзÖÀëδ½Ó´¥ÅàÑøÆ¿µÄADSCÓë¾ÅàÑøÆ¿ÅàÑøºóµÄADSCϸ°û±íÃæ±êÖ¾·¢ÉúÃ÷ ÏԱ仯£ºÐÂÏÊ·ÖÀëµÄADSCÖÐ90%ÒÔÉÏCD34ÑôÐÔ±í´ï£¬µ«¾3ÖÁ5ÌìÌåÍâÅàÑøºó±í´ïÃ÷ÏÔ ¼õÉÙ¡£Õâ¿ÉÄÜ¿ÉÒÔ½âÊÍÒÔÍù²»Í¬µÄÑо¿½á¹û¡£ 4 ADSCµÄ¶àϵ·Ö»¯ÄÜÁ¦ µ¥´Óϸ°û±íÃæ±êÖ¾ÊÇÎÞ·¨¼ø¶¨ADSCµÄ¡£³ýÁËÓëMSC´ó²¿·Ö±êÖ¾Ïàͬ£¬¶øÇÒÓë³É ÏËάϸ°û¸üÄÑÇø·Ö¡£ÒòΪ²»½öÔÚÐÎ̬ÏàËÆ£¬¶øÇÒ±íÃæÏ¸°û±êÖ¾¸üÊǽӽü[19]¡£Òò´Ë µ¥´¿ÒÔϸ°û²»±í±êÖ¾À´¼ø¶¨ADSCÃ÷ÏÔ²»×ã¡£ÓÉÓÚ¼ä³äÖʸÉϸ°ûÓë³ÉÌåϸ°û×î´óµÄÇø ±ðÔÚÓÚËü¾ßÓÐÏò²»Í¬µÄ¼äÖÊ×éÖ¯Èç¹Ç¡¢Èí¹Ç¡¢¼¡Èâ¡¢¼¡ë죬֬·¾¡¢Éñ¾¡¢Ñª¼°Ñª¹Ü ×éÖ¯¶àÏò·Ö»¯µÄÄÜÁ¦£¬Òò´Ë½øÐжàϵ¶¨ÏòÓÕµ¼Ö¤Ã÷ËüµÄ¶àÏò·Ö»¯ÄÜÁ¦¿ÉÄÜÊÇ½ÏºÃµÄ ¼ø¶¨¸Éϸ°ûµÄ·½·¨¡£²»Í¬Ñо¿ÒѾ֤Ã÷ƤÏÂÖ¬·¾×éÖ¯À´Ô´µÄ»ùÖÊϸ°ûͬMSCÒ»Ñù¾ßÓÐ ¶àϵ·Ö»¯µÄÄÜÁ¦¡£ÌåÍâÓÕµ¼Ñо¿Ö¤Ã÷£¬ÔÚרÃŵÄÓÕµ¼Òò×Ó´æÔÚµÄÌõ¼þÏ£¬ADSC¿ÉÒÔ ·Ö»¯ÎªÖ¬·¾Ï¸°û¡¢¹ÇºÍÈí¹Çϸ°û¡¢£¨ÐÄ£©¼¡Ï¸°û[6£¬7]¡£µ«ÓëMSCÏà±È£¬ADSC·Ö»¯Îª Ö¬·¾Ï¸°ûµÄЧÂʸü¸ß£¬¶øMSC·Ö»¯Îª¹ÇºÍÈí¹Çϸ°ûµÄÄÜÁ¦¸ü¸ß[20]¡£ ÁíÍ⣬»¹¿ÉÒÔ ÓÕµ¼·Ö»¯Îª¸Îϸ°û[21]¡¢Éñ¾Ï¸°ûµÈ[22]¡£ÕâЩÑо¿ÎªADSCµÄ¹ã·ºÓ¦ÓÃÍØ¿íÁË»ù´¡ ¡£ 5 ADSC¿ÉÒÔ×÷ÓÃÓÐЧµÄ»ùÒòÔØÌåÓÃÓÚ»ùÒòÖÎÁÆ Ñо¿»¹·¢ÏÖ£¬ADSC¿ÉÒÔ×÷ΪÓÐЧµÄÖÎÁÆ»ùÒòÔØÌ壬ÓëMSC²»ÏàÉÏÏ¡£Ò»ÏîÑо¿ [23]±È½ÏÁËADSCÓëMSC¶Ô5ÐÍÏÙ²¡ËØ¡¢ÖÂÁöÄæ×ªÂ¼²¡¶¾¼°Âý²¡¶¾µÄתȾЧ¹û·¢ÏÖ£¬ÔÚ MOIֵΪ14ʱÂý²¡¶¾¾Í¿ÉÒÔ»ñµÃ½Ï¸ßµÄתȾЧÂÊ(>90%)£¬ÊÇÖÂÁöÄæ×ªÂ¼²¡¶¾µÄ4ÖÁ5±¶ £¬¶øÇÒ²»Ó°Ïìϸ°ûµÄÉú³¤¡¢´«´úºÍ·Ö»¯¡£ÔÚÆäËüһЩÑо¿[24~26]ÖÐÔËÓÃÏÙ²¡¶¾×ªÈ¾ Ä¿µÄ»ùÒò¾ù»ñµÃÁ¼ºÃµÄЧ¹û¡£ 6 ADSCµÄÅÔ·ÖÃÚ¹¦ÄÜ ADSC ¿ÉÒÔ·ÖÃÚ¾ßÓÐÉúÎï»îÐÔµÄVEGF¡¢HGF¡¢TGF-¦ÂµÈ¶àÖÖ´Ù½øÑª¹ÜÐÂÉúµÄÒò ×Ó[27£¬28]£¬ÔÚȱÑõÌõ¼þÏ£¬VEGF·ÖÃÚÃ÷ÏÔÔö¼Ó¸ß´ï5±¶¡£ÓÃȱÑõÌõ¼þϵÄADSCÅàÑø ÉÏÇå¿ÉÒÔ¼ÓËÙÄÚÆ¤Ï¸°ûµÄÉú³¤£¬¼õÉÙÄÚÆ¤Ï¸°ûµÄµòÍö[28]¡£Hironori [13]µÈÓö¨Á¿ ʵʱPCR·ÖÎöµÄ·½·¨·¢ÏÖADSC³ýÁ˱í´ï½Ï¸ßˮƽµÄVEGF¡¢HGF¡¢TGF-¦¢Í⣬»¹¿ÉÒÔ¸ß ±í´ïPGF(placental growth factor),Öжȱí´ïFGF(fibroblast growth factor)-2 ºÍ Ang(angiopoietin)-1£¬µÍˮƽ±í´ïAng-2¡£ 7 ADSCµÄÃâÒßµ÷½Ú×÷Óà ͬMSCÒ»Ñù£¬ADSCÒ²¾ßÓÐÃâÒßÑ¹ÖÆÐ§Ó¦£¬¿ÉÒÔµ÷½ÚÒÆÖ²ÎËÞÖ÷²¡£¨GVHD£©¡£ Puissant B[29] µÈ·¢ÏÖ£¬ÔÚÌåÍâADSC²»½ö²»»á¼¤»îͬÖÖÒìÌåµÄ·ÇÏàÈݵÄÁܰÍϸ°û£¬ ¶øÇÒ¿ÉÒÔѹÒÖË¿ÁÑԴ̼¤ºóµÄ»ìºÏÁܰÍϸ°û·´Ó¦£¨MLR£©ºÍÁܰÍϸ°ûÔöÖ³·´Ó¦£¬²¢ÇÒ ÕâÖÖÒÖÖÆ×÷ÓóÊÖ¬·¾¸Éϸ°ûϸ°ûÊýÁ¿ÒÀÀµÐÔ£»ÕâÖÖ×÷ÓñØÐèÊÇÔÚÓëÁܰÍϸ°ûÓÐЧ½Ó ´¥µÄÌõ¼þÏ£¬ÈôÓÃͨ͸ÐÔĤ°ÑADSCÓëÁܰÍϸ°û¸ôÀ뿪£¬ÔòÒÖÖÆ×÷Óûá¼õÈõ¡£Ñо¿ÈÏ ÎªÕâÒ»×÷ÓÃÓëADSCµÄ·ÖÃÚ×÷ÓÃÎ޹ء£Yanez R[30]µÈͨ¹ý¶ÔСÊóGVHDµ÷½ÚµÄÑо¿·¢ÏÖ £¬Ð¡ÊóºÍÈ˵ÄADSCµÄÃâÒßµ÷½ÚÌØµãÓëÈ˵ĹÇËèMSCÏàËÆ£»¶øÇÒÈ˵ÄADSC¿ÉÒÔÒÖÖÆÈËË¿ ÁÑÔºÍÒìÌåTϸ°û´Ì¼¤ºóµÄǰÁܰÍϸ°ûµÄÔöÉúºÍϸ°ûÒò×ӵķÖÃÚ£»¸øÒÆÖ²°ëÏàºÏÔìѪ ¸Éϸ°ûµÄСÊóÊä×¢ADSC¿É¿ØÖÆÖÂËÀÐÔGVHDµÄ·¢Éú£¬¶øÓÐÑо¿[31]·¢ÏÖ¹ÇËèMSCÈ´²»ÄÜ ÒÖÖÆÔÚÌåGVHD¡£ADSCµÄÕâÒ»×÷ÓÃÌØµãËÆºõ¿ÉÓÃÒìÌåÒÆÖ²ÎïµÄÃâÒßÅųâÖÎÁÆ¡£ 8 רɫ֬·¾ÓëBATDCs Ö¬·¾×éÖ¯ÓÖ·ÖΪ°×ɫ֬·¾ºÍרɫ֬·¾£¬¶þÕßÔÚÉú³¤·¢ÓýÉÏ´æÔÚ»ùÒòµÄ²î±ð¡£°× ɫ֬·¾Ö÷ÒªÓëÄÜÁ¿µÄÖü´æÓйأ¬¶ø×ØÉ«Ö¬·¾ÓëÄÜÁ¿µÄÏûºÄÓйØ[32]¡£Yamada YµÈ[3 3]´Óרɫ֬·¾ÖзÖÀë³öÀ´µÄ»ùÖÊϸ°û±»ÃüÃûΪBATDCs£¨brown adipose tissue der ived cells£©£¬ÆäÖеÄCD29ÑôÐÔϸ°ûȺ±ÈMSCºÍÆêѪÀ´Ô´¸Éϸ°û¸üÈÝÒ×·Ö»¯ÎªÐļ¡¡£ ÔÚ¸ø¼±ÐÔÐĹ£´óÊóµÄ¹£ËÀÇøÐļ¡ÒÆÖ²CD29ÑôÐÔµÄBATDCºó£¬´óÊóµÄ¹£ÈûÃæ»ýºÍ×óÊÒÐÄ ¹¦ÄÜÁ½ÏîÖ¸±êµÄ¸ÄÉÆÏÔÖøÓÅÓÚ°×ɫ֬·¾ADSCϸ°ûÒÆÖ²×éºÍ¿Õ°×¶ÔÕÕ×é¡£Yamada YµÈ ½øÒ»²½Ñо¿[34]·¢ÏÖ£¬CD133ÑôÐÔµÄBATDCs±¾Éí²»½öÓнϸߵÄÐļ¡Ï¸°ûת»¯ÂÊ£¬¶øÇÒ £¬ÕâÒ»×éϸ°û»¹¿ÉÒÔͨ¹ýÓë¹ÇËèÀ´Ô´MSC¹²ÅàÑøÊ±Ðγɶþ¼ÛÑôÀë×Ó¹²¼ÛÁª½ÓÀ´ÓÕµ¼¹Ç ËèÀ´Ô´µÄMSCת»¯ÎªÐļ¡Ï¸°û¡£ 9 ADSCµÄÓ¦ÓÃÕ¹Íû ADSC¿ÉÒÔ·Ö»¯Îª¶àϵ×é֯ϸ°û£¬Õâ¶ÔÓÚ×é֯ϸ°ûÌæ´úºÍÆ÷¹ÙÐÞ¸´ÖÎÁÆÊÇÊ®·Ö ÓÐÒâÒåµÄ¡£Ñо¿·¢ÏÖADSCÔÚÌåÍâ¿ÉÒÔ·Ö»¯Îª×Ô·¢Ìø¶¯µÄÐļ¡Ï¸°û[35]£¬ÔÚÌå¿ÉÒÔת »¯Îª¾ßÓÐÐļ¡Ï¸°û½á¹¹²¢ÓеçѹÒÀÀµÐԵĸÆÍ¨µÀºÍ¼ØÍ¨µÀ[36]£¬Òò´ËĿǰÑо¿ÓÃAD SCÀ´ÖÎÁƼ±ÐÔÐĹ£ºÍÑÏÖØÐÄË¥¡£±¾ÊµÑéÊÒÔÚÇ°ÃæÑо¿[37]Öиø½áÔúǰ½µÖ§¶¯ÂöµÄÈ® ÐĹ£Ä£ÐÍ»µËÀÖܱßÇøÐÄÄÚĤÏÂ×¢ÉäADSC£¬·¢ÏÖ¿ÉÃ÷ÏÔ¸ÄÉÆÐĹ£ºóÐŦÄÜ¡£¶ø³É¹Ç×÷ ÓÿÉÄÜÓÃÓÚ¹Ç÷ĵÄÔÙÉúºÍÐÞ¸´[36]£»ADSCµÄÅÔ·ÖÃÚ×÷Óÿɱ»ÓÃÀ´ÖÎÁÆÈ±ÑªÐÔ¼²²¡£º ÓÐÑо¿[13£¬28]ÓÃADSCÖÎÁÆË«ÏÂ֫ȱѪ¶¯ÎïÄ£ÐÍÈ¡µÃÁ¼ºÃЧ¹û£¬¿ÉÏÔÖøÔö¼ÓȱѪÏ ֫µÄѪÁ÷Á¿¼°Ã«Ï¸Ñª¹ÜÃܶȡ£ADSCµÄ³ÉÖ¬×÷ÓÿÉÓÃÓÚÕûÐκÍÖØ½¨ÊÖÊõ[39]¡£ADSCµÄ ÃâÒßÑ¹ÖÆÐ§Ó¦Ê¹µÃADSC¿ÉÒÔʵÐÐÒìÌåÒÆÖ²£¬Ìá¸ßÁËADSCÁÙ´²Ó¦ÓõĿɲÙ×÷ÐÔ£¬»¹¿É ÒÔÔÚÆ÷¹ÙÒÆÖ²¿¹ÅÅÒì·´Ó¦Öз¢»Ó×÷Óá£ÁíÍ⣬ADSC¿ÉÒÔ×÷ΪÊʺϵĻùÒòÔØÌåΪ»ùÒò ÖÎÁÆÌṩÁËеÄ;¾¶[40]¡£ ×÷Õßµ¥Î»£º±±¾© 100853£¬½â·Å¾ü×ÜÒ½ÔºÐÄÄÚ¿Æ ×÷Õß¼ò½é£ºÇØÓîºì£¬ÄУ¬Ö÷ÖÎҽʦ£¬²©Ê¿Ñо¿Éú£¬Ñо¿·½Ïò£ºÐ£ËÀ¼°ÐÄÁ¦Ë¥½ß µÄ¸Éϸ°ûÖÎÁÆ¡£ ÊÀ½ç¼±Î£Öز¡Ò½Ñ§ÔÓÖ¾2007£»4£¨3£©£º1889-1892 |
» ²ÂÄãϲ»¶
ÖþÀÎÓªÑø°²È«ÏߣºÒÔ¾«×¼¼ì²â£¬»¤½¡¿µ»ùʯ
ÒѾÓÐ0È˻ظ´
ÍÆ¼öһЩ20ÖÖ°±»ùËá¼ì²âµÄʵ¼ÊÓ¦Óð¸Àý
ÒѾÓÐ0È˻ظ´
»¯Ñ§¹¤³Ì¼°¹¤Òµ»¯Ñ§ÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ111È˻ظ´
²»ºÏÀíÍÜ¿ÆÑÐʵÑéÖеÄȤÊ£ºÊµÑéÆ÷²ÄµÄ ¡°ÎÚÁú¡±
ÒѾÓÐ0È˻ظ´
²»ºÏÀíÍÜ¿ÆÑÐʵÑéÖеÄȤÊ£ººÍʵÑé²ÄÁ쵀 ¡°¶·ÖǶ·Ó¡±
ÒѾÓÐ0È˻ظ´
µ°°×Öʼì²â£º¾«×¼·ÖÎö£¬½âËøÉúÎï·Ö×ÓµÄÃÜÂë
ÒѾÓÐ0È˻ظ´
²»ºÏÀíÍÜ¿ÆÑÐʵÑé֮СÊóʵÑ飺ÑϽ÷Éè¼Æ£¬½âÎöÉúÃü»úÖÆµÄÖØÒªÔØÌå
ÒѾÓÐ0È˻ظ´
²»ºÏÀíÍÜ¿ÆÑÐʵÑéÖ®ÖØ½ðÊô¼ì²â£º¾«×¼É¸²é£¬ÊØ»¤½¡¿µÓë»·¾³µÄ·ÀÏß
ÒѾÓÐ0È˻ظ´
²»ºÏÀíÍÜ¿ÆÑÐʵÑéÖ®¡°ÍܲâÖØ½ðÊôÎÒ±³¹øÈýǧ¡±
ÒѾÓÐ0È˻ظ´
²»ºÏÀíÍÜ¿ÆÑÐʵÑéÖ®¡°ÊóÌÓÈý´ÎÎÒ·¢ÈýƪSCI¡±
ÒѾÓÐ0È˻ظ´
» ±¾Ö÷ÌâÏà¹ØÉ̼ÒÍÆ¼ö: (ÎÒÒ²ÒªÔÚÕâÀïÍÆ¹ã)

hansom999
Òø³æ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 594.1
- Ìû×Ó: 231
- ÔÚÏß: 5.4Сʱ
- ³æºÅ: 294989
- ×¢²á: 2006-11-11
- ÐÔ±ð: GG
- רҵ: Éñ¾ÉúÎïѧ
|
²Î¿¼ÎÄÏסª¡ª¿ÉÒÔÕÒµ½²»ÉÙ¾µäÎÄÕ 1 Doss MX, Koehler CI, Gissel C, et al. Embryonic stem cells: a promisin g tool for cell replacement therapy.J Cell Mol Med 2004 Oct-Dec;8(4):465 -473. 2 Siminiak T, Kalawski R, Fiszer D, et al. Autologous skeletal myoblast transplantation for the treatment of postinfarction myocardial injury: p hase I clinical study with 12 months of follow-up. Am Heart J 2004 Sep;1 48(3):531-537. 3 Zhang S, Jia Z, Ge J. Purified human bone marrow multipotent mesenchym al stem cells regenerate infarcted myocardium in experimental rats. Cell Transplant 2005;14(10):787-798. 4 van Laake LW, Hassink R, Doevendans PA, et al. Heart repair and stem c ells. J Physiol 2006 Dec 1;577(Pt 2):467-478. 5 Zuk PA, Zhu M, Mizuno H, et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng 2001;7:211-228 . 6 Zuk PA, Zhu M, Ashjian P,et al. Human adipose tissue is a source of mu ltipotent stem cells. Mol Biol Cell 2002;13:4279-4295. 7 Ogawa R, Mizuno H, Watanabe A, et al. Osteogenic and chondrogenic diff erentiation by adipose-derived stem cells harvested from GFP transgenic mice. Biochem Biophys Res Commun. 2004 Jan 23;313(4):871-877. 8 Safford KM, Hicok KC, Safford SD, et al. Neurogenic differentiation of murine and human adipose-derived stromal cells. Biochem Biophys Res Com mun 2002 Jun 7;294(2):371-379. 9 Xu Y, Malladi P, Wagner DR, et al. Adipose-derived mesenchymal cells a s a potential cell source for skeletal regeneration. Curr Opin Mol Ther 2005 Aug;7(4):300-305. 10 Lin TM, Tsai JL, Lin SD, et al. Accelerated growth and prolonged life span of adipose tissue-derived human mesenchymal stem cells in a medium using reduced calcium and antioxidants. Stem Cells Dev 2005 Feb;14(1):92 -102. 11 Guilak F, Awad HA, Fermor B, et al. Adipose-derived adult stem cells for cartilage tissue engineering. Biorheology 2004;41(3-4):389-399. 12 Kiwaki K, Novak CM, Hsu DK, et al. Galectin-3 stimulates preadipocyte proliferation and is up-regulated in growing adipose tissue.Obesity (Si lver Spring) 2007 Jan;15(1):32-39. 13 Hironori Nakagami, Ryuichi Morishita,et al. Adipose Tissue-Derived St romal Cells as a Novel Option for Regenerative Cell Therapy. Journal of Atherosclerosis and Thrombosis 2006; 13 (2):77-81. 14 stem cells from adipose tissue, and differentiated cells from said ce lls. US2004229351. 15 Gronthos S, Zannettino AC, Hay SJ, et al. Molecular and cellular char acterisation of highly purified stromal stem cells derived from human bo ne marrow.J Cell Sci 2003 May 1;116(Pt 9):1827-1835. 16 De Ugarte DA, Alfonso Z, Zuk PA, et al. Differential expression of st em cell mobilization-associated molecules on multi-lineage cells from ad ipose tissue and bone marrow.Immunol Lett 2003 Oct 31;89(2-3):267-270. 17 Seo MJ, Suh SY, Bae YC,et al. Differentiation of human adipose stroma l cells into hepatic lineage in vitro and in vivo. Biochem Biophys Res C ommun. 2005 Mar 4;328(1):258-264. 18 Planat-Benard V, Silvestre JS, Cousin B, et al. Plasticity of human a dipose lineage cells toward endothelial cells: physiological and therape utic perspectives. Circulation 2004; 109:656-663. 19 Ishii M, Koike C, Igarashi A, et al. Molecular markers distinguish bo ne marrow mesenchymal stem cells from fibroblasts[J].Biochem Biophys Res Commun 2005 Jun 24;332(1):297-303. 20 Liu TM, Martina M, Hutmacher DW, et al. Identification of common path ways mediating differentiation of bone marrow- and adipose tissue-derive d human mesenchymal stem cells into three mesenchymal lineages. Stem Cel ls 2007 Mar;25(3):750-760. 21 Seo MJ, Suh SY, Bae YC,et al. Differentiation of human adipose stroma l cells into hepatic lineage in vitro and in vivo. Biochem Biophys Res C ommun 2005 Mar 4;328(1):258-264 22 Kokai LE, Rubin JP, Marra KG. The potential of adipose-derived adult stem cells as a source of neuronal progenitor cells.Plast Reconstr Surg 2005 Oct;116(5):1453-1460. 23 Morizono K, De Ugarte DA, Zhu M, et al. Multilineage cells from adipo se tissue as gene delivery vehicles. Hum Gene Ther 2003 Jan 1;14(1):59-6 6. 24 Zhang X, Yang M, Lin L, et al. Runx2 overexpression enhances osteobla stic differentiation and mineralization in adipose--derived stem cells i n vitro and in vivo.Calcif Tissue Int 2006 Sep;79(3):169-178. 25 Zheng PH, Wei FC, Jin GY, et al. Experimental studies of human adipos e tissue-derived stromal cells transfected with ad-hBMP-2 gene. Hua Xi K ou Qiang Yi Xue Za Zhi 2006 Jun;24(3):195-198. 26 Yamashiro H, Inamoto T, Yagi M, et al. Efficient proliferation and ad ipose differentiation of human adipose tissue-derived vascular stromal cells transfected with basic fibroblast growth factor gene. Tissue Eng 2 003 Oct;9(5):881-892. 27 Rehman J, Traktuev D, Li J, Merfeld-Clauss S, Temm-Grove CJ, Bovenker k JE, Pell CL, Johnstone BH, Considine RV, and March KL: Secretion of an giogenic and antiapoptotic factors by human adipose stromal cells. Circu lation 2004; 109:1292-1298. 28 Nakagami H, Maeda K, Morishita R, et al. Novel autologous cell therap y in ischemic limb disease through growth factor secretion by cultured a dipose tissue-derived stromal cells . Arterioscler Thromb Vasc Biol. 200 5 Dec;25(12):2542-2547. 29 Puissant B, Barreau C, Bourin P, et al. Immunomodulatory effect of hu man adipose tissue-derived adult stem cells:comparison with bone marrow mesenchymal stem cells. Br J Haematol 2005 Apr;129(1):118-129. 30 Yanez R, Lamana ML, Garcia-Castro J, et al. Adipose tissue-derived me senchymal stem cells have in vivo immunosuppressive properties applicabl e for the control of the graft-versus-host disease.Stem Cells 2006 Nov;2 4(11):2582-2591. 31 Sudres M, Norol F, Trenado A, et al. Bone marrow mesenchymal stem cel ls suppress lymphocyte proliferation in vitro but fail to prevent graft- versus-host disease in mice.J Immunol. 2006 Jun 15;176(12):7761-7. 32 Sudres M, Norol F, Trenado A,et al. Bone marrow mesenchymal stem cell s suppress lymphocyte proliferation in vitro but fail to prevent graft-v ersus-host disease in mice. J Immunol 2006 Jun 15;176(12):7761-7767. 33 Yamada Y, Wang XD, Yokoyama S, et al. Cardiac progenitor cells in bro wn adipose tissue repaired damaged myocardium. Biochem Biophys Res Commu n 2006 Apr 7;342(2):662-670. 34 Yamada Y, Yokoyama SI, Wang XD, et al.Cardiac stem cells in brown adi pose tissue express CD133 and induce bone marrow non-hematopoietic cells to differentiate into cardiomyocytes Stem. Cells 2007 Feb 8;1-2. 35 Planat-Benard V, Menard C, Andre M, et al. Spontaneous cardiomyocyte differentiation from adipose tissue stroma cells.Circ Res 2004 Feb 6;94( 2):223-229. 36 Bai X, Pinkernell K, Song YH, et al. Genetically selected stem cells from human adipose tissue express cardiac markers. Biochem Biophys Res C ommun 2007 Feb 16;353(3):665-671. 37 ÏÄݼ£¬³Â¹â»Ô£¬Áõºê±óµÈ. Ö¬·¾¼äÆúÖʸÉϸ°ûÒÆÖ²¶ÔÈ®Ð£ËÀºóÐŦÄܵÄÓ°Ïì . ÖйúÁÙ´²¿µ¸´2006; 10£¨45£©£º33-35. 38 Weinzierl K, Hemprich A, Frerich B. Bone engineering with adipose tis sue derived stromal cells. J Craniomaxillofac Surg 2006 Dec;34(8):466-47 1. 39 Stosich MS, Mao JJ. Adipose tissue engineering from human adult stem cells: clinical implications in plastic and reconstructive surgery. Plas t Reconstr Surg 2007;119(1): 71-83. 40 Alpert JS. Are stem cells and genetic therapies ready for 'prime time '? Am J Med 2007 Feb;120(2):103-104. |

2Â¥2007-11-22 09:51:31
![]() ![]() ![]() |
3Â¥2007-11-24 06:33:54













»Ø¸´´ËÂ¥
